HOUSTON, March 15, 2021 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biopharmaceutical company specializing in the
development of novel treatments for primary and metastatic cancers
of the brain and central nervous system, today announced that
John Climaco, CEO of CNS
Pharmaceuticals will present at the inaugural Emerging Growth
Virtual Conference presented by M Vest LLC and Maxim Group LLC. The
conference will take place virtually on March 17th and 18th
and will feature roundtable discussions with C-suite executives
moderated by Maxim Research Analysts, fireside chats with live
Q&A, and presentations from hundreds of issuers both
domestically and internationally.
In addition to the presentation, Mr. Climaco will participate in
a live glioblastoma panel discussion on Wednesday, March 17th from
9:30-10:30 am ET.
Interested parties are invited to attend the virtual conference
and access exclusive content by becoming an M-Vest member and
registering HERE. To learn more about the event, please visit the
conference website: Emerging Growth Virtual Conference.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and
metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
clinical trial with Berubicin in malignant brain tumors, which
Reata conducted in 2006. In this trial the overall response rate of
stable disease or better was 44%. This 44% disease control rate was
based on 11 patients (out of 25 evaluable patients) with stable
disease, plus responders. One patient experienced a durable
complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a
limited patient sample size and, while promising, are not a
guarantee that similar results will be achieved in subsequent
trials. During 2021, CNS expects to commence a Phase 2 clinical
trial of Berubicin for the treatment of GBM in the U.S., while a
sub-licensee partner undertakes a Phase 2 trial (with extensive PK)
in adults and a first-ever Phase 1 trial in pediatric GBM patients
in Poland. Its second drug
candidate, WP1244, is a novel DNA binding agent that has shown in
preclinical studies that it is 500 times more potent than the
chemotherapeutic agent daunorubicin in inhibiting tumor cell
For more information, please visit www.CNSPharma.com.
About M Vest LLC
M Vest LLC is an online
investment bank and digital community built for issuers, investors,
and thought leaders to share information and access investment
opportunities through capital raisings of Regulation D and
Regulation A Offerings. Founded in 2017 and headquartered in
New York City, M-Vest provides
insights on current equity market trends, hosts presentations from
public companies, and provides access to capital for emerging
growth companies. M-Vest hosts live conferences and webinars
featuring CEOs discussing the latest developments in their
industries. M Vest LLC is a registered broker-dealer with the U.S.
Securities and Exchange Commission (SEC), is a member of FINRA and
SIPC, and is a sister company of Maxim Group, LLC.
About Maxim Group LLC
Maxim Group LLC is a
full-service investment banking, securities and wealth management
firm headquartered in New York.
The Firm provides a full array of financial services including
investment banking; private wealth management; and global
institutional equity, fixed-income and derivatives sales &
trading, equity research and prime brokerage services. Maxim Group
is a registered broker-dealer with the U.S. Securities and Exchange
Commission (SEC) and the Municipal Securities Rulemaking Board
(MSRB). Member of FINRA SIPC, and NASDAQ. To learn more about Maxim
Group, visit maximgrp.com.
View original content to download
SOURCE CNS Pharmaceuticals, Inc.